Search
Ulobetasol
go.drugbank.com/drugs/DB00596ApprovedUlobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...
Categories: Antipsoriatics for Topical Use, Corticosteroid Hormone Receptor AgonistsBerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalIt is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. … to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for
Categories: Adrenergic alpha-1 Receptor AntagonistsFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190486] The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before … [A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18.
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] It is used to identify tau NFT pathology in adults with cognitive impairment being evaluated for Alzheimer's disease and has not been established for evaluating non-Alzheimer's tauopathies. … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease
Asenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalIt is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. … Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with
Categories: Serotonin Receptor Agonists, Adrenergic alpha-1 Receptor AntagonistsNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesTerfenadine
go.drugbank.com/drugs/DB00342ApprovedWithdrawnIn the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Synonyms: (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-olCategories: Antihistamines for Systemic UseNeuropeptide Y
go.drugbank.com/drugs/DB11788ApprovedInvestigationalWithdrawnNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigationalPrescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. … [A181084] An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels in particular) is a significant risk factor for the development of CVD.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia